Search clinical trials for: Computer Assisted Learning (CAL) Module

Total 1746 results

National Cancer Institute (NCI)

Active, not recruiting

Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

Metastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma

United States
Emory University
National Cancer Institute (NCI)

Recruiting

Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial

Meningioma | Low Grade Glioma | Malignant Brain Neoplasm | Malignant Brain Glioma

United States
Emory University
National Cancer Institute (NCI)

Recruiting

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

Advanced Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Metastatic Hepatocellular Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma

United States
Northwestern University
National Cancer Institute (NCI)

Recruiting

N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy

Myxoid Liposarcoma | Synovial Sarcoma | Round Cell Liposarcoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Stage IV Hypopharyngeal Carcinoma AJCC... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Endometrial Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Uterine Corpus Malignant Mixed Mesodermal...

United States, Puerto Rico, South Korea
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

Poorly Differentiated Thyroid Gland Carcinoma | Refractory Differentiated Thyroid Gland Carcinoma | Refractory Thyroid Gland Carcinoma | Follicular Variant Thyroid Gland Papillary Carcinoma | Tall Cell Variant Thyroid Gland Papillary Carcinoma | Differentiated Thyroid Gland Carcinoma | Thyroid... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Malignant Solid Neoplasm | Rhabdoid Tumor | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Rhabdoid Tumor | Refractory Rhabdoid Tumor | Epithelioid Sarcoma | Kidney Medullary Carcinoma | Atypical Teratoid/Rhabdoid Tumor | Poorly Differentiated Chordoma | Recurrent Atypical... and other conditions

United States, Canada, Australia
National Cancer Institute (NCI)

Active, not recruiting

Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers

Recurrent Salivary Gland Carcinoma | Metastatic Salivary Gland Carcinoma | Unresectable Salivary Gland Carcinoma | Locally Advanced Salivary Gland Carcinoma

United States
National Cancer Institute LAO

Active, not recruiting

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

Locally Advanced Leiomyosarcoma | Unresectable Leiomyosarcoma | Metastatic Undifferentiated Pleomorphic Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Liposarcoma | Locally Advanced Undifferentiated Pleomorphic Sarcoma | Unresectable Liposarcoma | Unresectable Undifferentiated Pleomorphic... and other conditions

United States, Canada
Mayo Clinic
National Cancer Institute (NCI)

Not yet recruiting

Minimally Invasive Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Cancer, SOS5C Trial

Barrett Esophagus | Esophageal Adenocarcinoma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; Taiho Pharmaceutical Co., Ltd.

Active, not recruiting

TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer

Stage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8

United States
UNICANCER
National Cancer Institute, France

Active, not recruiting

PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer (NIRVANA-LUNG)

Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | Non-Small Cell Carcinoma of Lung, TNM Stage 4

France, Monaco
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

Oropharyngeal Squamous Cell Carcinoma | Squamous Cell Carcinoma | Basaloid Squamous Cell Carcinoma | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Papillary Squamous Cell Carcinoma | Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC... and other conditions

United States, Canada
National Cancer Institute (NCI)

Not yet recruiting

Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma

Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma
National Cancer Institute (NCI)

Active, not recruiting

Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer

Advanced Vaginal Adenocarcinoma | Advanced Vaginal Adenosquamous Carcinoma | Advanced Vaginal Squamous Cell Carcinoma | Stage IB2 Cervical Cancer AJCC v6 and v7 | Stage II Cervical Cancer AJCC v7 | Stage II Vaginal Cancer AJCC v6 and v7 | Stage III Vaginal Cancer AJCC v6 and v7 | Stage IIIB Cervical... and other conditions

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

Anal Basaloid Carcinoma | Anal Canal Cloacogenic Carcinoma | Anal Canal Squamous Cell Carcinoma | Anal Margin Squamous Cell Carcinoma | Stage I Anal Cancer AJCC v8 | Stage IIA Anal Cancer AJCC v8

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Advanced Pancreatic Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma

United States
Yuanquan Yang
Gateway for Cancer Research

Recruiting

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

Bladder Urothelial Carcinoma | Stage IIIA Bladder Cancer AJCC v8 | Muscle Invasive Bladder Carcinoma | Stage II Bladder Cancer AJCC v8

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

Prostate Adenocarcinoma | Stage IIIB Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Suspended

Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer

Breast Carcinoma | Colorectal Carcinoma

United States
Roswell Park Cancer Institute

Withdrawn

Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma

Soft Tissue Sarcoma

United States
National Cancer Institute (NCI)

Recruiting

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Sporadic Papillary Renal Cell Carcinoma

United States
M.D. Anderson Cancer Center

Recruiting

Evaluating the Impact of Limited Compared With Intense Post-Operative Surveillance on Patient-Reported Outcomes in Patients With Stage II-III Soft Tissue Sarcoma of the Trunk and Extremities

Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; Kuni Foundation

Active, not recruiting

Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA, IIB, or IIIA Melanoma

Pathologic Stage IIA Cutaneous Melanoma AJCC v8 | Pathologic Stage IIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIA Cutaneous Melanoma AJCC v8

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrioid Adenocarcinoma | Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Lymph Nodes | Metastatic Malignant Neoplasm in the Viscera | Sarcomatoid Renal Cell Carcinoma | Rhabdoid Tumor... and other conditions

United States, Puerto Rico
Ohio State University Comprehensive Cancer Center

Recruiting

Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cystic Neoplasms (ERASE-Chemo)

Pancreatic Cystic Neoplasm

United States
National Cancer Institute (NCI)

Recruiting

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Malignant Female Reproductive System Neoplasm | Recurrent Malignant Female Reproductive System Neoplasm

United States, Puerto Rico
National Cancer Institute (NCI)

Recruiting

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

Recurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Unresectable Triple-Negative Breast Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial

Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

Stage IV Lung Cancer AJCC v8 | Lung Non-Small Cell Squamous Carcinoma

United States
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Malignant Solid Neoplasm | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Canada, Puerto Rico, Australia
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors

Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Mayo Clinic

Recruiting

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Breast Carcinoma | Metastatic Malignant Neoplasm in the Leptomeninges

United States
National Cancer Institute (NCI)

Not yet recruiting

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

Refractory Multiple Myeloma | Recurrent Multiple Myeloma
National Cancer Institute (NCI)

Recruiting

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Stage IIIA Bladder Cancer AJCC v8 | Stage II Bladder Cancer AJCC v8 | Muscle Invasive Bladder Urothelial Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma | Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7 | Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage III Hypopharyngeal... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

Lymphoma | Unresectable Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
University of Washington

Active, not recruiting

Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

Estrogen Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7 | Primary or Recurrent Breast Carcinoma

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Ovarian Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Fallopian Tube High Grade Serous Adenocarcinoma | Primary Peritoneal Endometrioid Adenocarcinoma | Ovarian High Grade Endometrioid Adenocarcinoma and other conditions

United States, Puerto Rico, Japan
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

United States
University of Santiago de Compostela

Unknown

Methodology Antiseptic Application, Influence on Oral Biofilm.

Periodontitis | Gingivitis | Oral Biofilm

Spain
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity (STOPGAP II)

Gastric Adenocarcinoma | Peritoneal Carcinomatosis | Gastroesophageal Junction Adenocarcinoma

United States
Mayo Clinic

Recruiting

Q702 for the Treatment of Patients With Hematologic Malignancies

Primary Central Nervous System Lymphoma | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent... and other conditions

United States
Gabriel Tinoco

Recruiting

Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma

Sarcoma | Leiomyosarcoma

United States

Search clinical trials for: Computer Assisted Learning (CAL) Module

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations